Antiviral therapy human immunodeficiency virus infection children Antiretroviral therapy children early stage progress hours current standard therapy symptomatic children low standard likely clarifies optimal dosage ZDV different populations Children ZDV need monthly hematologic side effects common ill children role newer antiretrovirals ddI ddC likely different toxicity profile ZDV combination issue peripheral neuropathy lack easy test ddC ddI young preverbal children proposition ZDV optimum dosage timing ddC available regimens combination therapy Antiretroviral drugs dideoxynucleosides high-titer antiviral immunoglobulin technology available easy antisense oligomers new technology many hurdles agents laboratory clinic goal agents sites reverse transcriptase reasonable work new categories drug difficult slow meantime children HIV effective antiretroviral regimens available 